Article Text
Statistics from Altmetric.com
We read with interest the article by Marasco et al evaluating the prevalence of gastrointestinal (GI) symptoms and post-COVID-19 disorders of gut–brain interaction after hospitalisation for SARS-CoV-2 infection.1 The author found that COVID-19 is associated with a modest increased risk of irritable bowel syndrome (IBS).
Postinfectious IBS (PI-IBS) is a common disease in which GI symptoms begin after an episode of infective gastroenteritis. Acute gastroenteritis following infection with bacterial or viral pathogens is an important risk factor for IBS. Our previous study also confirmed that the odds of developing IBS are increased after acute GI infection.2 The first formal description of PI-IBS was published Chaudhary and Truelove.3 SARS-CoV-2 could also lead to GI symptoms, which involve abdominal pains, diarrhoea, nausea and vomiting. Our previous meta-analysis including 31 studies with 4682 COVID-19 patients found that SARS-CoV-2 infection was associated with diarrhoea, anorexia, abdominal pain and other GI symptoms.4 Schmulson et al first proposed criteria for post-COVID-19 IBS.5 There is an increasing amount of evidence that post-COVID-19 IBS is a significant global GI issue. The mechanisms of GI symptoms …
Footnotes
Correction notice This article has been corrected since it published Online First. The corresponding address and author affiliations have been corrected.
Contributors CD wrote the paper. CD and Y-HH had the original idea for the paper. All authors reviewed and approved the final draft of the paper.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.